Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2006-11-29 Regulatory Filings
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
AUTO-GENERATED PAPER DOCUMENT
Regulatory Filings
2006-11-29 English
Regulatory Filings 2006
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions the announcement of interim data from a Phase I/II trial and includes a press release as an exhibit. There are no financial statements or detailed financial data presented, only a press release announcement. The document length is 2571 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and often includes Form 8-K filings announcing events or press releases.
2006-11-15 English
Interim / Quarterly Report 2006
Interim / Quarterly Report Q3 2006
2006-11-09 English
FORM 4 SUBMISSION
Director's Dealing
2006-11-09 English
BIOGEN IDEC INC.
Major Shareholding Notification
2006-11-09 English
Earnings Release 2006
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 8, 2006. It announces preliminary financial results for the quarter ended September 30, 2006, and includes a press release as an exhibit. The text specifically states that the press release is attached and incorporated by reference, indicating this is an announcement of financial results rather than the full financial report itself. The document length is 2528 characters, which is relatively short and consistent with an earnings release announcement rather than a full report. Therefore, this document fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only.
2006-11-08 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.